T1	Participants 110 171	patients with hormonally untreated carcinoma of the prostate:
T2	Participants 367 456	patients with hormonally untreated carcinoma of the prostate and rising serum PSA levels.
T3	Participants 465 496	Eighty patients were randomised
T4	Participants 964 1024	Seventy patients completed the study (36 verum; 34 placebo).
T5	Participants 1580 1641	patients with hormonally untreated carcinoma of the prostate.
